These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 16801939)

  • 41. Medical therapy of prostate cancer. A review.
    Roscigno M; Sangalli M; Mazzoccoli B; Scattoni V; Da Pozzo L; Rigatti P
    Minerva Urol Nefrol; 2005 Jun; 57(2):71-84. PubMed ID: 15951731
    [TBL] [Abstract][Full Text] [Related]  

  • 42. First-line treatment of metastatic prostate cancer. Androgen suppression for symptomatic disease.
    Prescrire Int; 2013 Feb; 22(135):48-51. PubMed ID: 23444510
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Actualities in prostate cancer in ASCO annual meeting 2010].
    Pouessel D; Culine S
    Bull Cancer; 2010 Dec; 97(12):1563-72. PubMed ID: 21134822
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Chemotherapy for prostate cancer].
    Itoh N
    Nihon Rinsho; 2005 Feb; 63(2):293-7. PubMed ID: 15714981
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Metastatic castrate-resistant prostate cancer: dawn of a new age of management.
    Masson S; Bahl A
    BJU Int; 2012 Oct; 110(8):1110-4. PubMed ID: 22564337
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies.
    Gravis G; Boher JM; Chen YH; Liu G; Fizazi K; Carducci MA; Oudard S; Joly F; Jarrard DM; Soulie M; Eisenberger MJ; Habibian M; Dreicer R; Garcia JA; Hussain MHM; Kohli M; Vogelzang NJ; Picus J; DiPaola R; Sweeney C
    Eur Urol; 2018 Jun; 73(6):847-855. PubMed ID: 29475737
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [The treatment of castration-resistant prostate cancer].
    Petrányi Á
    Magy Onkol; 2012 Dec; 56(4):219-28. PubMed ID: 23236591
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Q-TWiST analysis of patients with metastatic castrate naive prostate cancer treated by androgen deprivation therapy with or without docetaxel in the randomised phase III GETUG-AFU 15 trial.
    Marino P; Sfumato P; Joly F; Fizazi K; Oudard S; Culine S; Habibian M; Boher JM; Gravis G
    Eur J Cancer; 2017 Oct; 84():27-33. PubMed ID: 28780479
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase 3 randomized trial evaluating second-line hormonal therapy versus docetaxel-estramustine combination chemotherapy on progression-free survival in asymptomatic patients with a rising prostate-specific antigen level after hormonal therapy for prostate cancer: an Eastern Cooperative Oncology Group (E1899), Intergroup/Clinical Trials Support Unit study.
    Walczak JR; Carducci MA;
    Urology; 2003 Dec; 62 Suppl 1():141-6. PubMed ID: 14747052
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Use of strontium-89 in endocrine-refractory prostate cancer metastatic to bone. Provincial Genitourinary Cancer Disease Site Group.
    Brundage MD; Crook JM; Lukka H
    Cancer Prev Control; 1998 Apr; 2(2):79-87. PubMed ID: 9765768
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Castration resistant prostate cancer 2011].
    Miller K
    Aktuelle Urol; 2011 Mar; 42(2):95-102. PubMed ID: 21437832
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Management of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): an Evolving Treatment Paradigm.
    Weiner AB; Nettey OS; Morgans AK
    Curr Treat Options Oncol; 2019 Jul; 20(9):69. PubMed ID: 31286275
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis.
    Rydzewska LHM; Burdett S; Vale CL; Clarke NW; Fizazi K; Kheoh T; Mason MD; Miladinovic B; James ND; Parmar MKB; Spears MR; Sweeney CJ; Sydes MR; Tran N; Tierney JF;
    Eur J Cancer; 2017 Oct; 84():88-101. PubMed ID: 28800492
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The management of hormone refractory prostate cancer.
    Newling DW
    Eur Urol; 1996; 29 Suppl 2():69-74. PubMed ID: 8717467
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.
    Tucci M; Bertaglia V; Vignani F; Buttigliero C; Fiori C; Porpiglia F; Scagliotti GV; Di Maio M
    Eur Urol; 2016 Apr; 69(4):563-573. PubMed ID: 26422676
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Current place of chemotherapy in the treatment of hormone-refractory metastatic prostate cancer].
    Breton X; Lechevallier E; Coulange C
    Prog Urol; 2005 Jun; 15(3):398-404. PubMed ID: 16097142
    [TBL] [Abstract][Full Text] [Related]  

  • 57. New principles in the treatment of prostate cancer--the oncologist's view.
    Widmark A
    Scand J Urol Nephrol Suppl; 2003; (212):23-7. PubMed ID: 12841324
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Treatment options for hormone-refractory prostate cancer].
    Heidenreich A; Ohlmann CH
    Urologe A; 2005 Nov; 44(11):1303-4, 1306-14. PubMed ID: 16237541
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Therapeutic options and controversies in the management of prostate cancer].
    Peyromaure M; Thiounn N
    Rev Prat; 2003 Dec; 53(20):2263-7. PubMed ID: 15018081
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Optimal treatment for elderly high-risk prostate cancer patients].
    Soga N; Sugimura Y
    Gan To Kagaku Ryoho; 2007 Mar; 34(3):387-92. PubMed ID: 17353629
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.